Softwr

Research · head to head

Benchling vs Paige

Benchling logo

Benchling

Research

R&D cloud for biotechnology research and molecular biology

From
Free
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Only Benchling has a free tier, so it costs nothing to try first.
  • Each has a real cost: Benchling enterprise pricing is not published and is widely reported as expensive relative to general-purpose research tools; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Benchling covers Electronic lab notebook, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Benchling and Paige actually diverge.

Attributes where Benchling and Paige differ
AttributeBenchlingPaige
Starting priceFreeOn request
Pricing modelFree for academics, quoted for organisationsquote
Free tierYesNo
PlatformsWeb, CloudWeb, Cloud, On-premise
CategoryResearchHealthcare

Identical on both: user rating (Not yet rated).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Benchling

  • Electronic lab notebook
  • Molecular biology tools
  • Registry
  • Inventory
  • Workflows
  • Insights

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Benchling

  • Biotechnology research organisations working with sequences and constructs dailynot Paige
  • Academic laboratories needing a shared electronic notebook at no costnot Paige
  • Companies replacing paper notebooks and spreadsheet sample trackingnot Paige
  • R&D organisations wanting research data structured enough to analyse laternot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Benchling
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Benchling
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Benchling
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Benchling

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Benchling

  • Enterprise pricing is not published and is widely reported as expensive relative to general-purpose research tools
  • Not a substitute for a regulated QC LIMS, and organisations that assume otherwise discover the gap during an inspection readiness review
  • The free academic tier is genuinely useful, which makes the jump to enterprise pricing feel steeper when a lab commercialises
  • Configuration of the registry and workflows is a real project for larger deployments, not a signup
  • Chemistry support is weaker than biology, so chemistry-led organisations should evaluate carefully

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Benchling

Free
  • AcademicFree
    • ELN
    • Molecular biology tools
    • Sequence design
  • Enterprise$undefined/year
    • Registry
    • Inventory
    • Workflows

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Benchling if

  • You need electronic lab notebook.
  • You want to start without paying.
  • You work on Web, Cloud.
  • You also want molecular biology tools.
Benchling review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Benchling or Paige better?
Neither clearly leads. Benchling starts at Free and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Benchling or Paige?
Benchling has a free tier; the other does not. Paid plans start at Free for Benchling and On request for Paige.
Does Benchling or Paige run on more platforms?
Benchling runs on Web, Cloud. Paige runs on Web, Cloud, On-premise.
Can I use Benchling for free?
Yes. Benchling has a free tier, so you can try it without paying. Paige starts at On request.
What is Benchling best used for?
Benchling is most often used for biotechnology research organisations working with sequences and constructs daily, academic laboratories needing a shared electronic notebook at no cost, companies replacing paper notebooks and spreadsheet sample tracking, r&d organisations wanting research data structured enough to analyse later. Of those, biotechnology research organisations working with sequences and constructs daily and academic laboratories needing a shared electronic notebook at no cost are not what Paige is typically brought in for.
What can Benchling do that Paige cannot?
Benchling covers Electronic lab notebook, Molecular biology tools, Registry, Inventory. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Benchling: Is Benchling free?

For qualifying academic use, yes, and that tier is genuinely usable rather than a trial. Commercial organisations are quoted.

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Benchling: Is it a LIMS?

Not in the regulated sense. It handles research sample tracking well, but laboratories needing inspected quality control testing should evaluate a traditional LIMS such as LabWare or STARLIMS.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Benchling: Why did it spread so quickly in biotech?

It treats sequences, plasmids and constructs as first-class objects rather than attachments. Scientists adopted it at the bench, which is unusual for research software and is why it arrived without procurement driving it.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Benchling: What does enterprise cost?

Not published, and reported as expensive. Budget for it as an enterprise platform rather than as a per-seat notebook.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Benchling: Does it support chemistry?

Less well than biology. Chemistry-led organisations should evaluate it carefully against tools built for that discipline.

Share

Related pages

More on Benchling

More on Paige

Keep looking

Other head to heads